AU2023233122B2 — Osimertinib for use in the treatment of non-small cell lung cancer
Assigned to AstraZeneca AB · Expires 2025-07-24 · 1y expired
What this patent protects
#$%^&*AU2023233122B220250724.pdf##### ABSTRACT The specification relates to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for use in the treatment of EGFR TKI-naïve patients with locally-advanced or metastatic EGFR mutation-positive non-small ce…
USPTO Abstract
#$%^&*AU2023233122B220250724.pdf##### ABSTRACT The specification relates to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) for use in the treatment of EGFR TKI-naïve patients with locally-advanced or metastatic EGFR mutation-positive non-small cell lung cancer (NSCLC), wherein the EGFR TKI is administered in combination with pemetrexed and platinum chemotherapy. 20 23 23 31 22 2 1 Se p 20 23 ABSTRACT The specification relates to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) 2023233122 21 Sep 2023 for use in the treatment of EGFR TKI-naïve patients with locally-advanced or metastatic EGFR mutation-positive non-small cell lung cancer (NSCLC), wherein the EGFR TKI is administered in combination with pemetrexed and platinum chemotherapy.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.